Kesimpta is a medication specifically designed to treat multiple sclerosis (MS), particularly the relapsing forms of the disease. One of the key questions many patients and caregivers have is whether Kesimpta can reduce MS lesions, which are areas of damage in the brain and spinal cord caused by the immune system attacking nerve cells.
Kesimpta works by targeting a specific type of immune cell called B-cells. These B-cells are part of the immune system and, in MS, they mistakenly contribute to the inflammation and damage of nerve cells. Kesimpta is a monoclonal antibody that binds to a protein called CD20 found on the surface of B-cells. By binding to CD20, Kesimpta leads to the depletion of these B-cells from the bloodstream. This reduction in B-cells helps to lower the immune system’s attack on the nervous system, which in turn can reduce the formation of new lesions and potentially allow some healing or stabilization of existing damage.
Clinical studies have shown that patients treated with Kesimpta experience fewer relapses and a decrease in the number of new or enlarging lesions visible on MRI scans. These lesions are the hallmark of MS activity and are closely linked to disease progression and symptoms. By reducing the number of active lesions, Kesimpta helps slow the progression of the disease and can improve the quality of life for many patients.
The process of lesion reduction with Kesimpta is tied to its ability to modulate the immune system. By depleting B-cells, Kesimpta reduces the inflammatory response that leads to nerve damage. Over time, this can result in fewer new lesions forming. It is important to note that while Kesimpta can reduce lesion activity and slow disease progression, it does not cure MS or reverse all existing damage. The goal of treatment is to manage the disease, prevent relapses, and maintain neurological function.
Kesimpta is administered as a once-monthly injection under the skin, which makes it convenient for many patients compared to some other treatments that require intravenous infusions. The ease of use and targeted mechanism of action have made Kesimpta a valuable option in the landscape of MS therapies.
Patients considering Kesimpta should discuss with their healthcare providers the potential benefits and risks. While it is effective at reducing lesions and relapses, it can also affect the immune system’s ability to fight infections, so monitoring and regular check-ups are essential.
In summary, Kesimpta reduces MS lesions by depleting B-cells that contribute to the immune attack on the nervous system. This leads to fewer new lesions, reduced relapse rates, and slower disease progression in many patients with relapsing MS. The treatment represents a targeted approach to managing the disease by addressing one of the key drivers of inflammation and nerve damage.
